Detail akcie Graybug Vision Rg online

Business Summary: CalciMedica, Inc. is a clinical-stage biopharmaceutical company. The Company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for inflammatory and immunologic diseases. The Company's technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury. Its lead product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The Company is conducting a Phase IIb trial (called CARPO) for acute pancreatitis (AP) with systemic inflammatory response syndrome (SIRS), as well as supporting the ongoing Phase I/II asparaginase-induced pancreatic toxicity (AIPT) study (called CRSPA).
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Calcimedica Inc revenues was not reported. Net loss increased 99% to $18.8M. Higher net loss reflects PHARMACEUTICAL PREPARATIONS segment loss increase of 4% to $18.7M. Basic Earnings per Share excluding Extraordinary Items decreased from -$0.85 to -$1.27.